Next Article in Journal
The Isolation and Characterization of a Novel Psychrotolerant Cellulolytic Bacterium, Microbacterium sp. QXD-8T
Previous Article in Journal
The Antimicrobial Resistance of Enterotoxigenic Escherichia coli from Diarrheal Patients and the Environment in Two Geographically Distinct Rural Areas in Bangladesh over the Years
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 12
Issue 2
10.3390/microorganisms12020302
Review Report
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Cohort Profile: The Zurich Primary HIV Infection Study

Microorganisms 2024, 12(2), 302; https://doi.org/10.3390/microorganisms12020302
by Matt C. Freind 1, Carmen Tallón de Lara 1, Roger D. Kouyos 1,2, David Wimmersberger 1, Hebert Kuster 1, Leonardo Aceto 3, Helen Kovari 3, Markus Flepp 3, Adrian Schibli 4, Benjamin Hampel 5, Christina Grube 5, Dominique L. Braun 1,2,† and Huldrych F. Günthard 1,2,*,†
Reviewer 1:
Eun-Young Kim
Reviewer 2: Anonymous
Microorganisms 2024, 12(2), 302; https://doi.org/10.3390/microorganisms12020302
Submission received: 15 December 2023 / Revised: 22 January 2024 / Accepted: 23 January 2024 / Published: 31 January 2024
(This article belongs to the Section Virology)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

The authors demonstrate that the Zurich Primary HIV Infection (ZPHI) study is a well-characterized and prospective cohort as an extensively studied Primary HIV Infection cohort.

 

It is a valuable article describing how the primary HIV infection cohort plays a critical role in determining the course of the disease and contributes to capturing the improvement of protection against HIV infection and the understanding of the early stages of HIV infection and pathogenesis. As a minor comment, it could be beneficial if the authors add a comparative analysis with other available HIV cohort studies to assess the representativeness.

 

This article provides insights into further improvement of HIV translational research and HIV medicine.

Author Response

Please see attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

Thank you for allowing me the opportunity to review this article. The topic of this article is important to the field, and will help fill a gap in the literature. The information is presently clearly. I have a few minor questions/comments below.

Questions/comments

Inclusion criteria: were persons that identify their gender as nonbinary, transgender, ect. excluded from the study? What about persons that are intersex?

The clinical trials.gov website shows different inclusion/exclusion criteria. Please update the inclusion/exclusion to include all criteria or update clinical trials.gov.

How was medications for the investigation on the impact of early cART determined? Randomly or doctor assigned based on guidelines before the 2012 change?

You may want to move the antiretroviral section below the data collection or add more detail about the enrollment. Something to reflect that the cART was based on their enrollment in one cohort study with 3 protocols that also include a polit study. It was confusing about the participants until I got to the section that detailed the different studies.

Discussion – 1st sentence, correct the apostrophe to a comma.  

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop